Skip to main content

Table 3 Change of clinical parameters after admission

From: A case of tamoxifen-induced hypertriglyceridemia monitoring the changes in lipoprotein fractions over time

Parameters Units In hospital After discharge
Under dosing tamoxifen 7 days after tamoxifen withdrawal 2 months after dosing pemafibrate
Parameters related with lipid metabolism
 TC mg/dL 341 282 234
 TG mg/dL 964 675 231
 HDL-C mg/dL 34 33 46
 LDL-C mg/dL 68 114 156
 non-HDL-C mg/dL 307 249 188
 RLP-C mg/dL 59.0 11.3
 Apo A-I mg/dL 148   153
 Apo B mg/dL 158 155 142
 Apo C-II mg/dL 21.8 14.5 9.5
 Apo C-III mg/dL 63.4 33.9 20.0
 Apo C-III/C-II ratio   2.9 2.3 2.1
 Apo E mg/dL 14.7   5.5
 LDL-C/ Apo B ratio   0.51 0.73 1.10
Lipoprotein fraction test (PAGE method)
 HDL % 18 10 17
 BAND 1 % 4 16  
 LDL % 16 12 44
 MIDBAND % 39 35 24
 VLDL % 23 27 15
 LDL-MI   0.67 0.60 0.37
Other parameters
 HbA1c % 7.3 7.0
 Cre mg/dL 1.40   1.00
 eGFR ml/min/1.75m2 32.9   47.5
 P-Amy U/L 72 53
  1. TC total cholesterol, TG triglyceride, HDL-C high density lipoprotein- cholesterol, LDL-C low density lipoprotein- cholesterol, RLP-C remnant lipoprotein- cholesterol, Apo apolipoprotein, PAGE polyacrylamide gel electrophoresis, LDL-MI LDL-migration index, Cre creatinine, eGFR estimated glomerular filtration rate, P-Amy pancreatic amylase. LDL size was assessed by the migration of the LDL fraction, and LDL-MI was identified by the migration distance of LDL fraction relative to the HDL fraction